Current Pharmacological Advances in the Treatment of Cardiac Arrest by Koliantzaki, Iosifina et al.
Current Pharmacological Advances  
in the Treatment of Cardiac Arrest
Iosifina Koliantzaki, MD, Spyros G. Zakynthinos, MD, PhD, 
Spyros D. Mentzelopoulos, MD, PhD
A b s t r A c t
Cardiac arrest requires immediate treatment, in order to prevent patient death. Car-
diac arrest outcomes still remain very poor, especially when the patient requires vaso-
pressor treatment. Vasopressors have been advocated, in order to increase the coro-
nary and cerebral perfusion pressure during cardiopulmonary resuscitation (CPR). 
Recent data suggest an epinephrine-related benefit with respect to short- and long-
term outcomes, only when epinephrine is administered within the first 10 min of col-
lapse. Also, increasing the epinephrine dosing interval from 3-5 to 6-10 min during 
CPR may be associated with improved long-term outcomes. In the in-hospital setting, 
the combination of vasopressin, epinephrine, and corticosteroid supplementation 
during and after CPR (in the presence of post-resuscitation shock) may be superior 
to epinephrine alone during CPR. The use of new formulations of amiodarone, po-
tentially devoid of serious hypotensive effects, may contribute to increased rates of 
sustained return of spontaneous circulation in patients with ventricular fibrillation/
pulseless ventricular tachycardia cardiac arrest. Encouraging preliminary results have 
been reported on the use of beta blockers in patients with shockable cardiac arrest. 
Other potentially promising pharmacological interventions include the use of cari-
poride, nitrates (and particularly inhaled nitric oxide), noble gases, levosimendan, and 
erythropoietin. The purpose of the current paper is to review the clinical and labora-
tory evidence that support new and potentially useful pharmacological interventions 
during CPR.
I N t r O D U c t I O N
Despite important advances in prevention, cardiac arrest remains a substantial 
public health problem and a leading cause of death in many parts of the world.1 Car-
diac arrest continues to be an all-too-common cause of premature death, and small 
incremental improvements in survival can translate into thousands of lives saved every 
year. In each resuscitation scenario, four concepts should always apply:
 1. Activate the resuscitation team.
 2. Perform cardiopulmonary resuscitation (CPR).
 3. Evaluate heart rhythm and perform early defibrillation as indicated.
 4. Deliver advanced life support (ALS), e.g., endotracheal intubation, intravenous 
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(IV) access and drugs, and specific treatment of reversible 
cardiac arrest causes.
There is an ongoing discussion concerning interventions 
to improve survival rates. Some interventions have strong 
evidence such as prompt initiation of high quality chest com-
pressions,2 early defibrillation,3,4 minimizing interruption in 
chest compressions,2 and post resuscitation care initiatives.5-7 
Conversely, interventions such as intravenous vasopressor 
agents have a controversial role in resuscitation.8,9 In this 
paper, we summarize current experimental and clinical data 
on drugs during CPR.
v A s O P r e s s O r s
To date, no controlled trials have shown that administra-
tion of any vasopressor agent at any stage during the manage-
ment of any cardiac arrest rhythm, i.e. ventricular fibrillation 
(VF)/pulseless ventricular tachycardia (VT), pulseless electri-
cal activity (PEA), and asystole, increases the rate of neurologi-
cally favorable survival to hospital discharge.
e P I N e P h r I N e
Epinephrine is a non-selective alpha and beta adrenergic 
agonist, and its value in resuscitation is attributed largely to 
the alpha-1 receptor mediated vasoconstrictive properties.8 
It has been used in CPR since 18969 and it is integrated into 
advanced life support guidelines for adult cardiac arrest.10,11 
Apart from increased rates of return of spontaneous circula-
tion (ROSC),10-12 there are limited data supporting epinephrine 
effectiveness with respect to long-term survival.12
Epinephrine augments coronary blood flow generated by 
chest compressions during CPR. After a few minutes of car-
diac arrest, arterial tone collapses and epinephrine or another 
vasoconstrictor is essential for the restoration of spontaneous 
cardiac activity.13-15 Epinephrine increases aortic pressure 
during chest compressions via alpha-adrenergic constriction 
of arterioles, which increases pressure in the proximal aorta.16 
Increased aortic pressure may shunt more blood into the coro-
nary arteries and increase the probability of ROSC.
Beta-adrenergic effects of epinephrine are generally unde-
sirable for cardiac arrest patients. Beta-adrenergic stimulation 
causes tachycardia, tachyarrhythmias and increased myocardial 
oxygen consumption, exacerbating a possible existing myocar-
dial insult.17 It also renders ventricular pacing foci irritable 
and increases the probability of ventricular arrhythmias post-
resuscitation.18 Epinephrine may also promote thrombogenesis 
and platelet activation.19 Acute coronary syndromes are the 
most common cause of sudden cardiac arrest in a series of 
resuscitated out-of-hospital cardiac arrest patients.20 Increased 
platelet activity might worsen acute coronary ischemia.
Vasoconstriction induced by epinephrine prolongs is-
chemia in some tissue beds during and after CPR.21 Regarding 
the brain, the alpha-1 agonist activity of epinephrine has been 
associated with reduced perfusion of the cerebral microcircula-
tion,22,23 which may explain previously reported, unfavorable 
results on neurological outcomes.24,25
Epinephrine has been compared with several vasoactive 
medications that might increase coronary perfusion pressure 
in clinical trials.26-28 In particular, studies have found no con-
sistent superiority of epinephrine over other alpha-adrenergic 
agonists or more recently vasopressin.
Nonrandomized studies24,29-33 suggest that neurological out-
comes may be worse with epinephrine. Also, two randomized 
clinical trials failed to show a beneficial effect of epinephrine 
on long-term survival. In the first study, which took place in 
Oslo, Norway, adult, out-of hospital cardiac arrest victims were 
randomly assigned to receive intravenous (IV) drugs versus 
no IV drugs.17,34 Among the 851 patients who were included 
in the primary analysis, 418 had IV access and 433 had no IV 
access. In 45 patients (10%) assigned to no IV drugs, an IV 
drug administration did occur later-on during resuscitation. 
In 74 patients (17%) assigned to IV drugs, no line could be 
established prior to the end of resuscitation.
Patients with vs those without an IV line had higher rates 
of ROSC (40% vs 25%) and admission to the intensive care 
unit (ICu) (30% vs 20%). However, the proportions of pa-
tients discharged from the hospital (10.5% vs 9.2%) or alive 
at 1 year (10% vs 8%) were similar. The most commonly 
administered IV drug was epinephrine (79% of the patients 
with intravenous access).
In a post-hoc analysis published later-on, the authors 
compared outcomes between patients who actually received 
epinephrine and those who did not receive epinephrine.17 Pa-
tients who received epinephrine (n=367) versus those who did 
not receive epinephrine (n =481) were more likely to achieve 
hospital admission (odds ratio - OR: 2.5, 95% confidence inter-
val - CI: 1.9-3.4) but less likely to survive to hospital discharge 
(OR: 0.5, 95% CI: 0.3-0.9).
In the second study, which was conducted in Australia, 
adult, out-of-hospital cardiac arrest patients were randomized 
to receive 1-mg boluses of epinephrine or placebo.35 Blinding 
was achieved by supplying paramedics with identical vials 
containing either 1 mg/mL of epinephrine or saline placebo. 
From 602 randomized patients, 534 (epinephrine group, 
n=272) had available documentation and were included in 
the primary analysis.
Epinephrine vs placebo group patients were more likely 
to achieve ROSC (OR=3.4; 95% CI 2.0-5.6) but not survival 
to hospital discharge (OR=2.2; 95% CI 0.7-6.3). This study 
did not achieve its intended enrolment target because of prob-
lems with funding and loss of support from the participating 
paramedics.
Notably, a recent, retrospective analysis of prospectively 
collected, population-based data (n=49165 adults with wit-
nessed, out-of-hospital cardiac arrest of cardiac origin) showed 
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that epinephrine administration within 10 minutes of collapse 
was associated with improved survival to hospital discharge 
(OR 1.73; 95% CI: 1.46-2.04) and good neurological outcome 
(OR 1.39, 95% CI 1.08-1.78).36 In most studies, good neuro-
logical outcome is defined as a cerebral performance category 
score of 1 or 237 at hospital discharge. Epinephrine efficacy 
is also supported by another, large, propensity analysis that 
showed a slightly improved, neurologically favorable survival 
with epinephrine use vs no use (0.7% vs 0.4%; OR: 1.57, 95% 
CI: 1.04-2.37) in 9058 pairs of patients with non-shockable 
out-of-hospital cardiac arrest.38
Lastly, another recent review of 20909 in-hospital cardiac 
arrest events showed that increasing the epinephrine dosing 
interval from the guideline-recommended of 3-5 minutes to 
6-10 minutes was associated with improved survival to hospital 
discharge (adjusted ORs 1.30 to 2.17; 95% CIs: 1.02-1.62 to 
1.65-2.92).39 Consequently, both the optimal timing of the first 
dose of epinephrine and its optimal dosing interval warrant 
further determination in future, prospective, randomized 
clinical trials.
vA s O P r e s s I N  w I t h / w I t h O U t  s t e r O I D s
Vasopressin causes contraction of vascular smooth mus-
cle through stimulation of the V1a receptors and increases 
smooth muscle responsiveness to catecholamines.40 Endog-
enous vasopressin and cortisol levels are higher in patients 
achieving ROSC.41 Furthermore, experimental data suggest 
that vasopressin improves vital organ perfusion during CPR, 
post-ROSC survival, and neurological recovery.42-47
In the 2010 American Heart Association guidelines for 
CPR, the authors state ‘’Because the effects of vasopressin 
have not been shown to differ from those of epinephrine in 
cardiac arrest, 1 dose of vasopressin 40 units intravenous/
intraosseous may replace either the first or second dose of 
epinephrine in the treatment of cardiac arrest’’ (Class IIb, 
Level of Evidence A).11 On the other hand, authors of the 
European Resuscitation Council (ERC) guidelines, do not 
support the use of any other vasopressor instead of or in ad-
dition to epinephrine.10 They emphasize on the scarcity of 
data to support or refute the use of any vasopressor during 
cardiopulmonary resuscitation efforts. The use of epinephrine 
is still recommended by the ERC guidelines, based solely on 
animal data and increased short-term survival in humans.31,34
In a meta-analysis conducted by our group,48 we included 
data from 6 high-methodological quality randomized con-
trolled trials27,28,49-52 that enrolled a total of 4475 patients. 
These trials assigned adults with cardiac arrest to treatment 
with either a vasopressin-containing regimen (vasopressin-
group), or epinephrine alone (control-group). Subgroup 
analyses were conducted according to initial cardiac rhythm 
and time from collapse to drug administration less than 20 
minutes.48 Vasopressin use was not associated with any overall 
benefit or harm. However, in asystole, vasopressin vs control 
was associated with higher long-term survival (OR: 1.80, 95% 
CI: 1.04–3.12). Furthermore, in asystolic patients with a time 
from collapse to drug administration of less than 20 minutes, 
vasopressin vs control increased the rates of sustained ROSC 
(data available from 2 trials; OR = 1.70, 95% CI = 1.17–2.47) 
and long-term survival (data available from 3 trials; OR = 2.84, 
95% CI = 1.19–6.79).
A more recent, multicenter clinical trial recruited 727 
participants and evaluated vasopressin (40 Iu) vs epinephrine 
(1 mg) given to out-of-hospital, non-traumatic, adult cardiac 
arrest patients brought to the Emergency Department,53 ad-
ditional epinephrine was administered as required according 
to resuscitation guidelines.53 Eleven participants from the vaso-
pressin group (2.9%) and 8 participants from the epinephrine 
group (2.3%) survived to hospital discharge with (OR: 1.72, 
95% CI: 0.65–4.51). After adjustment for race, medical history, 
bystander CPR, and pre-enrolment epinephrine, vasopressin-
treated patients were more likely to achieve hospital admis-
sion than epinephrine-treated patients (OR: 1.43, 95% CI: 
1.02–2.04). Sub-group analysis suggested improved outcomes 
with vasopressin treatment in participants with prolonged 
arrest times. The authors emphasized the need for further 
studies on the effect of vasopressin combined with therapeutic 
hypothermia in patients with prolonged cardiac arrest.
In a previous single-center, randomized, controlled study 
conducted by our group,52 combined vasopressin-epinephrine 
during CPR and corticosteroid supplementation during and 
after CPR vs epinephrine alone during CPR and no steroids 
resulted in improved overall survival to hospital discharge. 
Patients in the vasopressin-steroids epinephrine (VSE) group 
had more frequent ROSC, and attenuated post-resuscitation 
systemic inflammatory response52,54 and organ dysfunction.52 
This preliminary study could not reliably assess VSE efficacy 
with respect to neurologically favorable survival to hospital dis-
charge. We addressed this question in a subsequent, 3-center 
study of vasopressor-requiring, in-hospital cardiac arrest;55 the 
study protocol was identical to that of our preliminary study.52 
This randomized, controlled trial included 268 consecutive 
patients with cardiac arrest requiring epinephrine according 
to resuscitation guidelines (from 364 patients assessed for 
eligibility). Patients received either vasopressin (20 Iu/CPR 
cycle) plus epinephrine (1 mg/CPR cycle; cycle duration ap-
proximately 3 min) (VSE group, n = 130) or saline placebo plus 
epinephrine (1 mg/CPR cycle; cycle duration approximately 3 
min) (control group, n = 138) for the first 5 CPR cycles after 
randomization, followed by additional epinephrine if needed. 
During the first CPR cycle after randomization, patients in 
the VSE group received 40 mg of methylprednisolone and 
patients in the control group received saline placebo. Shock 
after resuscitation was treated with stress-dose hydrocortisone 
(VSE group) or saline placebo (control group). Patients in the 
VSE group vs patients in the control group had higher prob-
ability of ROSC for 20 minutes or longer (83.9% vs. 65.9%; 
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OR: 2.98, 95% CI: 1.39-6.40) and survival to hospital discharge 
with a cerebral performance category score of 1 or 2 (13.9% 
vs. 5.1%; OR: 3.28; 95% CI 1.17-9.20).
Both VSE studies exhibit limitations: results refer only to 
in-hospital cardiac arrest, there was no assessment of CPR 
quality, the VSE protocol did not allow a precise determina-
tion of the relative contribution of vasopressin and steroids to 
the positive VSE group outcomes, there were some baseline 
imbalances with respect to cardiac arrest etiology and present-
ing rhythm, potentially favoring the VSE group,52,55-58 and there 
was no pre-specified determination of 1-year outcomes. Thus, 
additional clinical evaluation is warranted before the incorpo-
ration of the VSE protocol to the resuscitation guidelines.59
Additional CPR drug regimens supported by animal data 
and potentially warranting further clinical evaluation may in-
clude combined epinephrine, vasopressin, and nitroglycerin,60 
epinephrine and atenolol,61 epinephrine and nitroglycerin,62 
and epinephrine and levosimendan.63
A N t I A r r h y t h M I c s
Antiarrhythmics are a heterogeneous group of drugs that 
affect cardiac automaticity and conduction, and are used for 
ventricular and atrial arrhythmias.
A M I O D A r O N e
Amiodarone is a potent antiarrhythmic agent with a com-
plex electrophysiological and pharmacological profile.64 It is pri-
marily a Vaughan Williams Class III agent; it acts by inhibiting 
the inward potassium current. It also blocks sodium and calcium 
channels and has antiadrenergic properties (noncompetitive 
blockade of alpha and beta receptors). It prolongs the action 
potential and the QT interval, and increases the refractoriness 
of the cardiomyocytes. Amiodarone is effective in suppressing 
both supraventricular and ventricular tachyarrhythmias.
The treatment of choice for ventricular fibrillation (VF) 
is defibrillation. However, amiodarone can be useful in 
shock refractory VF. In the Amiodarone in Out-of-Hospital 
Resuscitation of Refractory Sustained Ventricular Tachy-
cardia (ARREST) trial, amiodarone was shown to improve 
survival to hospital admission (when compared to placebo) 
in patients with shock-refractory VF.65 On the basis of these 
results, the current VF guidelines (both AHA and ERC) 
suggest amiodarone in shockable rhythms not responsive 
to three countershocks and vasopressor therapy (Class IIb, 
Level of Evidence B).10,11 An initial dose of 300 mg (IV or 
intraosseously) can be followed by a second dose of 150 mg. 
Amiodarone is more effective than lidocaine in VF or pulse-
less ventricular tachycardia (VT).11,66
Amiodarone has a relatively slow onset of action with a 
maximum effect at 15 minutes after IV injection. A possible 
reason of drugs’ failure to improve long-term survival is that 
they are given too late during ALS.67 Also amiodarone’s 
efficacy as rescue medication may be hampered by its hypo-
tensive and bradycardic activity, especially in patients with 
heart failure.68
Indeed, in the ARREST trial, amiodarone treated patients 
experienced more bradycardia and hypotension.65 Hypotension 
is the dose-limiting adverse event of IV amiodarone and may 
be partly due to the formulation’s cosolvents (i.e. polysorbate 
80 and benzyl alcohol). To minimize hypotension, the initial 
loading dose of amiodarone is diluted to 1.5 mg/ml and infused 
over 10 minutes.
As rapid drug administration may be important, efforts 
have been focused on the development of alternative ami-
odarone formulations. In 2008, an amiodarone formulation 
with sulfobutylether-7-beta-cyclodextrin (Nexterone®) was 
approved by the FDA, with the same label indications as the 
previously approved formulation of amiodarone. The formula-
tion’s diluent is hemodynamically and electrophysiologically 
inert.69 Captisol-enabled amiodarone as rapid IV bolus (150 
mg) and as continuous infusion is bioequivalent to the previous 
approved formulation of amiodarone, with identical electro-
physiologic effects,70 but no hypotensive effects.71,72
L I D O c A I N e
The Amiodarone versus Lidocaine in Prehospital Ven-
tricular Fibrillation Evaluation (ALIVE) trial involved 347 
patients randomized to either amiodarone (initial bolus dose 
of 5mg/Kg followed, if needed, by a second bolus dose of 2.5 
mg/Kg) or lidocaine (initial bolus dose of 1.5 mg/Kg, repeated 
once, if needed). More patients treated with amiodarone sur-
vived to hospital admission, compared with patients treated 
with lidocaine (23% versus 12%, P <0.005).67
A recent systematic review of the literature regarding ami-
odarone and lidocaine and their effectiveness in cardiac arrest 
patients, reached the conclusion that “Amiodarone may be 
considered in patients with refractory VF/VT, defined as VF/
VT/VF not terminated by defibrillation, or recurring VF/VT. 
There is inadequate evidence to support or refute the use of 
lidocaine and other antiarrythmic agents in the same settings”.73
According to current guidelines,10,11 if amiodarone is not 
available, the sodium channel blocker lidocaine may be given 
(initial IV bolus: 1-1.5 mg/kg, followed by additional IV boluses 
of 0.5-0.75 mg/kg every 5-10 minutes and up to a total dose of 
3 mg/kg). A large effectiveness trial comparing amiodarone, 
lidocaine, and placebo in non-traumatic out-of-hospital cardiac 
arrest due to shock-refractory VF/VT is currently underway.
N I f e K A L A N t
Nifekalant is a selective potassium channel blocker. In a 
porcine model of induced VF, nifekalant and amiodarone were 
equally effective in improving short-term survival and postre-
suscitation cardiac function.74 Nifekalant was reported to be 
associated with improved short-term survival when it was used 
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in the management of shock-refractory VF/VT cardiac arrest.75,76
b e t A  b L O c K e r s
Two small, clinical, prospective human studies tested the 
effects of beta blockade against regular therapy in patients 
presenting with electrical storm. Electrical storm, defined as 
recurrent multiple VF episodes, often occurs in patients with 
recent myocardial infarction, and bears a poor prognosis. In the 
intervention group of the first study,77 sympathetic blockade 
(left stellate ganglionic blockade, esmolol, or propranolol) 
resulted in a decline in the mean number of VF episodes from 
over 20 to 2.6±1.7 per day (P <0.01). In contrast, 91% of 
patients in the control group continued to have VF episodes. 
At the end of the first year of follow-up, 18/27 patients in the 
beta blockade group were still alive, compared with 1/22 in 
the control group. In the other human trial,78 42 consecutive 
patients with electrical storm refractory to regular ALS therapy 
received intravenous landiolol in increasing doses (starting at 
2.5 μg/kg/min; maximum dose was 80 μg/kg/min), subsequently 
titrated to the minimum infusion rate required for arrhyth-
mia control. The study protocol was ineffective in 9 patients 
(21%), who died of arrhythmia. From the 33 responders, 21 
received carvedilol and 12 were started on bisoprolol, with 
oral beta-blocker administration immediately after stabiliza-
tion. Eight of these 33 patients (19%) died afterwards from 
multiple organ failure or infection, and 25 (60%) survived to 
hospital discharge.
A recently published review on the use of beta-blockers in 
cardiac arrest with shockable rhythms concluded that available 
human studies may point toward a beneficial effect of beta-
blockade in patients, which is in accordance with the results 
from the majority of relevant clinical case reports and animal 
experimental studies.79 However, high quality human trials are 
warranted, in order to reliably evaluate the potential usefulness 
of the beta-blockers in cardiac arrest. Indeed, beta-blockers 
may counteract the potentially deleterious beta-adrenergic 
effects of epinephrine, which may contribute to the post-
resuscitation myocardial dysfunction and the recurrence of 
life-threatening arrhythmias.
M A g N e s I U M  s U L P h A t e
According to current AHA and ERC guidelines, IV 
magnesium sulfate can be given exclusively for the treatment 
of irregular/polymorphic VT associated with prolonged QT 
interval.10,11,80,81 A recent meta-analysis concluded that IV 
magnesium sulfate vs placebo does not affect short- or long-
term outcomes of cardiac arrest.82
O t h e r  D r U g s
c A r I P O r I D e
Ventricular arrhythmias commonly occur after successful 
resuscitation from cardiac arrest with a reported incidence of 
VF as high as 79%.83 Some studies have reported an inverse 
relationship between the number of VF episodes and survival.83 
Along with reperfusion arrhythmias, the myocardium during 
the post resuscitation period also suffers varying degrees of 
global dysfunction that can compromise hemodynamic func-
tion.84,85 Resuscitation from cardiac arrest is commonly associ-
ated with varying severity of reversible left ventricular systolic 
and diastolic dysfunction.86,87 These electrical and mechanical 
abnormalities occur early in the post-resuscitation phase, and 
contribute to re-arrest and early post-ROSC mortality.86
The Na+-induced, cytosolic Ca2+ overload plays a promi-
nent role in the ischemia/reperfusion injury of the cardio-
myocytes. Electrophysiologically, there are repolarization 
abnormalities, including shortening of action potential dura-
tion; post-resuscitation ventricular arrhythmias are partly due 
to cytosolic Ca2+ accumulation.88-91 This reflects a reverse 
operation of the sarcolemmal Na+-Ca2+ exchanger.92,93 More 
specifically, during ischemia, intracellular acidosis develops 
rapidly and the sarcolemmal sodium-hydrogen exchanger 
isoform-1 (NHE-1) is activated, with concomitant inactiva-
tion of the Na+-K+ ATPase.94,95 Na+ accumulates intracellu-
larly, activating the Na+-Ca2+ exchanger, and increasing the 
cytosolic Ca2+. This can lead to detrimental cardiomyocyte 
injury, such as contracture and necrosis. During myocardial 
reperfusion, these events are magnified because the return 
of blood flow lowers the extracellular H+ concentration, thus 
stimulating the NHE-1 to extrude more intracellular H+ ion. 
This leads to further intracellular Na+ entry, and ultimately 
intracellular Ca2+ overload (through the Na+-Ca2+ exchanger) 
and cardiomyocyte injury.96
NHE-1 inhibition could reduce sarcolemmal Na+ entry and 
spare ATP use by the Na+-K+ pump, thus retarding intracellu-
lar ATP depletion and the consequent ischemic contracture.97 
Reduced cytosolic Na+ overload might attenuate/prevent 1) 
the associated mitochondrial injury;98 and 2) the reverse-mode 
operation of the Na+-Ca2+ exchanger; this causes cytosolic 
Ca2+ overload, as well as an outward (repolarizing) current 
that shortens action potential duration and promotes electri-
cal instability. Excellent reviews have been written on the 
mechanisms of NHE-1 activation and the potential benefits 
of its inhibition.99,100
Cariporide is a potent and specific NHE-1 inhibitor. Sev-
eral experimental studies showed beneficial effects of NHE-1 
inhibitors given at the onset of resuscitation.94,95,101-112 During 
VF, NHE-1 inhibition attenuated/prevented the development 
of ischemic contracture, and post-resuscitation ventricular 
ectopic activity, episodes of recurrent VF, and myocardial dys-
function. NHE-1 inhibition facilitated successful resuscitation 
and improved survival.105 Clinical studies on NHE-1 inhibition 




N I t r A t e s
The greatest proportion of in-hospital, post-resuscitation 
mortality is caused by global ischemic brain injury, whereas 
both myocardial dysfunction and systemic inflammation 
predispose to poor neurological outcome.113 Mechanisms of 
post-resuscitation brain injury include excitotoxicity, free radi-
cal formation, pathological activation of proteases, and cell 
death signalling.114 The injurious pathways include disruption 
of the blood–brain barrier, neuro-inflammation, and delayed 
neuro-degeneration.113,115
Nitrite therapy limits cellular injury and apoptosis after 
ischemia and reperfusion (I/R).116 It has been proven to be 
cytoprotective in numerous animal models of focal I/R in-
jury, including rodent heart, brain, liver and kidney, canine 
heart, and primate brain.116-120 Systemic nitrite reduction by 
ceruloplasmin knockout or dietary nitrate/nitrite elimination 
increased infarction volume in the liver and heart after experi-
mental ischemia.121,122 These studies indicate that physiological 
systemic nitrite levels modulate host resilience to ischemia. 
The established safety of human and animal nitrite dosing123 
and its potent effects in limiting major organ injury suggest 
that nitrite represents an ideal candidate for the treatment of 
cardiac arrest.
Nitric oxide (NO) is produced from NO synthases (NOS, 
i.e. NOS1, NOS2, and NOS3). NO exerts a number of effects 
that would be expected to be beneficial during I/R injury.124 NO 
is a potent vasodilator which inhibits platelet and leukocyte ac-
tivation and adhesion, inhibits reactive oxygen species (ROS)-
producing enzymes, and directly scavenges ROS.125 Studies 
using NOS3 knockout mice showed that NOS3 deficiency 
aggravates I/R injury in the brain and heart,126,127 whereas 
cardiomyocyte-specific overexpression of NOS3 attenuated 
postresuscitation myocardial and neurological dysfunction in 
NOS3-deficient mice.128
Several recent studies are also consistent with a nitrite 
treatment/NO associated benefit in experimental cardiac 
arrest.60,62,129-134 Likely mechanisms of brain protection may 
involve the primary intra-cellular target of NO, i.e. soluble 
guanylate cyclase,132 or increased levels of neuronal nitrite and 
S-nitrosothiols.133 The neuroprotective effects of hypothermia 
seem to be at least partly mediated through enhanced NOS3 
signalling.134 Also, inhaled NO (40 ppm) improves neurological 
outcomes during concurrent use of hypothermia.134
In contrast to NO, NO-donor compounds may induce 
systemic vasodilation and hypotension, frequently precluding 
their use in the setting of cardiac arrest-associated hemody-
namic instability. On the other hand, inhaled NO is a selec-
tive pulmonary vasodilator that does not produce systemic 
hypotension when inhaled at concentrations of up to 80 ppm 
in multiple species, including man.135 The absence of systemic 
vasodilation during NO inhalation is due to the rapid scaveng-
ing of NO by hemoglobin in the blood.
Some NO, once inhaled, may escape scavenging by hemo-
globin and be converted to relatively stable NO metabolites 
(e.g., nitrite and S-nitrosothiols) that can regenerate NO in the 
periphery.136 NO inhalation has been associated with marked 
increases in the arterial blood concentration of NO metabo-
lites.137 Also, regenerated NO may exert regional vasodilating 
effects. Indeed, a recent study by Terpolilli et al,138 showed 
that NO inhalation prevented ischemic brain injury in mice 
and sheep by selective dilatation of collateral arterioles. The 
aforementioned, promising, experimental results provide a 
robust background for a possible, future evaluation of nitrates/
NO in the clinical setting
N O b L e  g A s e s
A major post-ROSC threat is global cerebral hypoxia-
ischemia,139,140 which causes necrosis or apoptosis of neuronal 
tissue.141-143 Cognitive dysfunction, a permanent or transient 
inability to perform daily activities144,145 is an expected result, 
especially due to hippocampal injury.146-148 It is imperative that 
survival rates after cardiac arrest and attempts to improve these 
rates be seen under the spectrum of long term neurological 
recovery. Many experimental and clinical studies focus on 
novel strategies to improve these rates.
Medical gases (hydrogen, helium, argon, xenon) have a 
wide scope of applications in medicine, such as anesthesiol-
ogy, hyperbaric oxygen therapy, neuroprotection and hypo-
thermia.149
1. Xenon
Xenon is a noble gas with anesthetic properties. It is a 
potent and specific competitive antagonist of the N-Methyl-
D-Aspartate (NMDA) receptor.150,151 The NMDA receptor is 
a ligand-gated ion channel, which allows the selective passage 
of both Na+ and Ca2+ ions into cells. These receptors are vital 
in neural plasticity, learning, memory, pain and, most crucially, 
glutamate-mediated neurotoxicity.152 Xenon also inhibits two 
other subtypes of glutamate receptor channels, namely the 
AMPA(α-Amino-3-hydroxy-5-Methyl-4-isoxazole-Propionic 
Acid) and KA (KAinate) receptors,153 as well as the recently 
identified two-pore potassium channels, TREK.154,155 It also 
activates ATP-sensitive K+ channels.156
In vivo studies using subanesthetic (i.e. 50%) concentra-
tions of Xenon showed promising results against cardiac arrest-
induced cerebral ischemia,148 and neurobehavioral dysfunction 
due to a brain insult.156 Xenon attenuates the ischemia-
induced, neurotransmitter release,154 and antagonizes NMDA 
receptors.148,157-159 Xenon’s blockade of NMDA receptors is a 
key factor,150 since NMDA receptors are primarily involved in 
the initiation and progression of apoptosis of neural tissue.160,161 
Xenon treatment reduces perivascular inflammation in the 
putamen and caudate nucleus of pigs resuscitated from cardiac 
arrest.148 Xenon has a higher efficacy in the cortex rather than 
the subcortex due to differences in the vascularity and density 
of the NMDA receptors.162 Xenon also contributes to cardio-
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vascular stability,163 and myocardial protection.164
Xenon has also been investigated in combination with 
therapeutic hypothermia. Studies have shown that Xenon 
augments neuroprotection when combined with hypothermia 
in animal hypoxia-ischemia models.165-167 Hobbs et al have dem-
onstrated that a combination therapy of hypothermia (32°C) 
with inhalation of 50% Xenon for 3 hours increases neuropro-
tection from 37% (hypothermia only) to 76% (hypothermia 
combined with xenon inhalation).168 Hypothermia decreases 
the release of glutamate that binds to NMDA receptors. It also 
reduces the release of glycine which assists glutamate to act 
on the NMDA receptor. Since Xenon is a NMDA receptor 
antagonist, hypothermia’s role of decreasing neurotransmit-
ter and Xenon’s role of receptor blockage converge on an 
antiapoptotic pathway.168
Arola et al assigned patients resuscitated from out-of-hos-
pital VF/VT cardiac arrest to either therapeutic hypothermia 
alone or in combination with xenon (target concentration of 
at least 40%) for 24 hours.169 The frequency of serious adverse 
events, including inhospital mortality, status epilepticus and 
acute kidney injury, was similar in both groups and there were 
no unexpected serious adverse reactions to xenon. In addition, 
xenon did not induce significant conduction, repolarization, 
or rhythm abnormalities. The median dose of norepinephrine, 
heart rate, and incremental changes in cardiac troponin-T 
were lower in xenon-treated patients. The authors concluded 
that xenon treatment in combination with hypothermia is 
feasible and has favorable cardiac features in survivors of VF/
VT cardiac arrest.
2. Argon
Argon is another noble gas, but unlike xenon, it is quite 
abundant in earth’s atmosphere. As with xenon, no side adverse 
effects on its applications on humans have been reported.170 
Argon’s lack of anesthetic properties and low cost, make it a 
more attractive candidate than xenon, in the research of noble 
gases’ organoprotective properties.171
Prior experimental studies suggested that Argon may 
exert protective effects on the brain, heart and kidney.172-176 
Ristagno et al investigated the effects of post resuscitation 
treatment with argon on neurological recovery in a porcine 
model of cardiac arrest with an underlying acute myocardial 
infarction. They concluded that post-resuscitation treatment 
with argon allowed for a faster and complete neurological 
recovery, without detrimental effects on hemodynamics and 
respiratory gas exchange.177
The already published, preliminary data on Xenon and 
Argon are encouraging for further evaluation of their efficacy 
in the clinical setting.
c O r t I c O s t e r O I D s
Recent laboratory data and clinical results are consistent 
with a possible, low-dose corticosteroid-associated, benefit in 
cardiac arrest, especially in patients with post-resuscitation 
shock.178
Cardioprotective effects of glucocorticoids in the acute 
setting of myocardial I/R have been shown experimentally with 
regard to structural and functional myocardial damage.179-186 A 
more recent meta-analysis of human data from 11 controlled 
trials suggested a possible mortality benefit for corticosteroid 
treatment of myocardial infarction.187
Glucocorticoids attenuate leukocyte/endothelium interac-
tions,188-191 as well as the generation and release of inflamma-
tory cytokines and mediators.192-195 The post–cardiac arrest 
syndrome has similarities to septic shock, but the efficacy of 
corticosteroids remains controversial in patients with sepsis 
as well.54,196-198 The Surviving Sepsis Campaign guidelines 2012 
for the management of severe sepsis and septic shock suggest 
stress-dose hydrocortisone therapy (daily dose: 200 mg) only 
for patients who are poorly responsive to fluid and vasopressor 
therapy,199 a state of shock very usual in cardiac arrest patients 
in the post resuscitation phase.
The mechanisms underlying the post-cardiac arrest syn-
drome involve a whole body ischemia and reperfusion that 
triggers a systemic inflammatory response.187,188,196,197,200 Alto-
gether, the high levels of circulating cytokines, the presence 
of endotoxin in plasma, and the dysregulated production of 
cytokines found in cardiac arrest patients resemble the im-
munological profile found in patients with sepsis.200-202
In our recent, in-hospital cardiac arrest studies,52,55 we 
administered 40 mg of methylprednisolone during CPR (in 
combination with vasopressin / epinephrine – see section on 
vasopressors), and stress dose hydrocortisone (300 mg/day for 
a maximum of 7 days followed by gradual taper) to patients 
fulfilling a clearly defined criterion for post-resuscitation 
shock. Patients with evidence of myocardial infarction received 
a 3-day course of stress dose hydrocortisone (followed by 
gradual taper), in order to prevent any potential retardation 
of infarct healing. Compared to control, the postresuscitation 
shock subgroups of the VSE groups had improved post-arrest 
hemodynamics and central venous oxygen saturation,52,55 
post-arrest cytokine levels52 and organ/system function53,56 
and survival to hospital discharge with favorable neurological 
recovery.52,55 Accordingly, pooled subgroup results show more 
VSE patients [23/103 (22.3%)] than control patients [6/88 
(6.8%)] with good functional outcome [Hazard ratio for death 
during follow-up or severe cerebral disability/vegetative state: 
0.64; 95% CI 0.46-0.88; P=0.006].52,55
As already mentioned above, due to the VSE combi-
nation, we could not separately assess glucocorticoid ef-
ficacy.52,55,202 Therefore, a large, multicenter, randomized, 
placebo-controlled evaluation of stress-dose glucocorticoid 
supplementation in cardiac arrest is still needed.178,202 Such 
a study should provide definitive results on the efficacy, and 
appropriate dosage and timing of steroid administration. 
Lastly, although there is no published data suggestive of a 
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glucocorticoid-associated neuroprotection,52,55,178,201,202 recent 
laboratory results suggest that the biosynthetically related 
estrogens may actually mitigate the effects of global cerebral 
ischemia,203,204 and renal ischemia as well.205
L e v O s I M e N D A N
Levosimendan, a new calcium sensitizer, exerts positive 
inotropic and lusitropic effects in failing human myocardium 
without increase in energy expenditure.206 The documentation 
regarding levosimendan is one of the largest ever on the safety 
and efficacy of a pharmacological agent in acute heart failure 
syndromes.206 Recently, levosimendan, was tested alone in an 
asphyxia model of cardiac arrest.207 Levosimendan increased 
cerebral blood flow, reduced neuronal injury, and improved 
neurological outcome, when compared to placebo. Findings 
seem to be independent of inflammatory effects because no 
effects of levosimendan on cerebral or systemic inflammation 
could be detected. Another study reports favorable effects of 
levosimendan on cardiac function.208 It seemed to have better 
inotropic and lusitropic effects when compared to epinephrine, 
during rewarming from deep hypothermic circulatory arrest 
with cardiopulmonary bypass. Another study compared epi-
nephrine to the combination of levosimendan and epinephrine 
in an experimental model of ventricular fibrillation.63 The 
combination therapy seemed to significantly improve the 
rates of ROSC (P = 0.01). The coronary perfusion pressure, 
saturation of peripheral oxygenation and brain regional oxygen 
saturation were significantly higher during cardiopulmonary 
resuscitation in the group that received the combination of 
levosimendan and epinephrine. Epinephrine combined with 
levosimendan and atenolol, administered during resuscitation, 
in a pig model of cardiac arrest, resulted in improved 48-hour 
survival and improved postresuscitation cardiac function.61
e r y t h r O P O I e t I N
Several studies have shown that erythropoietin, besides 
its critical role in hematopoiesis, also activates potent cell 
survival mechanisms during ischemia and reperfusion through 
genomic and non-genomic signaling mechanisms in a broad 
array of organs and tissues including the brain,209-212 heart213-222 
and kidney.223,224
In one rat model of asphyxial cardiac arrest, the administra-
tion of erythropoietin 15 minutes before the arrest was associ-
ated with improved 72-hour survival.225 Another animal study 
demonstrated improved postrescusitation myocardial function 
and 3-day survival. During the latter study, erythropoietin was 
administered 3 minutes after ROSC.226
A human study of erythropoietin administered during 
CPR showed improved short-term and long-term survival 
when compared with (nonrandomized) concurrent, and ret-
rospective controls.227 In this study, an IV bolus of 90,000 Iu 
erythropoietin was given to out-of-hospital patients within 
2 minutes of EMS arrival on the scene. The erythropoietin 
group, when compared to placebo and matched historic con-
trols, was associated with more effective chest compressions 
leading to higher ROSC rate, 24-hour survival and survival 
to hospital discharge. However, the validity of these results is 
obscured by serious methodological flaws of the study, as the 
study design was abandoned in the interim and drugs were 
given in a non-randomized and open fashion allowing for 
various sources of bias.
The neuroprotective action of erythropoietin was tested in 
out-of-hospital patients in a matched control study by Cariou 
et al.228 Erythropoietin-alpha (40,000 Iu, repeated every 12 
hours for the first 48 hours) was administered after sustained 
ROSC and compared to placebo, while all the patients were 
admitted to the ICu and treated with mild hypothermia. After 
28 days there was a trend toward better neurological recovery 
in the erythropoietin -treated group, which never reached 
statistical significance; thus, there was no difference in terms 
of survival. Thrombocytosis occurred in 15% of patients in 
the Epo-group, and was associated with one case of arterial 
vascular thrombosis.228 A large, randomized, controlled, phase 
III trial investigating the possible neuroprotective role of 
erythropoietin-alpha in comatose survivors of cardiac arrest 
is currently underway.
Due to its anti-apoptotic, anti-inflammatory, and anti-oxi-
dant properties, as well as its angiogenic action, erythropoietin 
may have a role in neuroprotection and cardioprotection. In 
this regard, erythropoietin represents a promising agent as part 
of the post-resuscitation treatment of cardiac arrest patients.229
c O N c L U s I O N s
Early recognition and activation, uninterrupted chest 
compressions of appropriate depth (at least 51 mm) and rate 
(100/min), while still allowing for full chest recoil, and early 
defibrillation (when the rhythm is shockable), are components 
of CPR proven to increase the probability of neurologically 
favorable survival. Effective chest compressions remain the 
mainstay of CPR. In between the 5-yearly guideline updates 
and despite the abundance of publications, it hasn’t been feasi-
ble to definitively support or refute the use of ANY single drug 
during cardiopulmonary resuscitation. use of vasopressors as 
described in international guidelines published by AHA or 
ERC, is based mainly on experimental and observational data. 
The efficacy of a regimen of vasopressin, epinephrine during 
CPR, and of steroids “during/after CPR” requires further con-
firmation in a multinational trial involving multiple healthcare 
systems. It is widely accepted that short-term benefits of CPR 
drug regimens may be converted into long-term outcomes by 
optimizing management in the postarrest period; thus, further 
research is warranted in this direction.
244
HOSPITAL CHRONICLES 9(4), 2014
r e f e r e N c e s
1. Lloyd-Jones D, Adams RJ, Brown TM. AHA Statistics Com-
mittee and Stroke Statistics Subcommittee. Heart disease and 
stroke statistics–2010 update: a report from the AHA. Circula-
tion 2010; 121:e46–e215.
2. Berg RA, Hemphill R, Abella BS, et al. Part 5: adult basic life 
support: 2010 AHA Guidelines for Cardiopulmonary Resusci-
tation and Emergency Cardiovascular Care. Circulation 2010; 
122(Suppl 3):S685-S705.
3. Bunch TJ, White RD, Gersh BJ, et al. Long-term outcomes of 
out-of-hospital cardiac arrest after successful early defibrilla-
tion. N Engl J Med 2003; 348:2626–2633.
4. Krittayaphong R, Saengsung P, Chawaruechai T, et al. Early de-
fibrillation: a key for successful outcome of in-hospital cardiac 
arrest. J Med Assoc Thai 2009; 92:S1–S5.
5. Bobrow BJ, Kern KB. Regionalization of postcardiac arrest 
care. Curr Opin Crit Care 2009; 15:221–222.
6. Nichol G, Soar J. Regional cardiac resuscitation systems of 
care. Curr Opin Crit Care 2010; 16:223–230.
7. Walters JH, Morley PT, Nolan JP. The role of hypothermia in 
post-cardiac arrest patients with return of spontaneous circula-
tion: a systematic review. Resuscitation 2011; 82:508–516.
8. Attaran RR, Ewy GA. Epinephrine in resuscitation: curse or 
cure? Future Cardiol 2010; 6:473–482.
9. Penson PE, Ford WR, Broadley KJ. Vasopressors for cardio-
pulmonary resuscitation. Does pharmacological evidence sup-
port clinical practice? Pharmacol Ther 2007; 115:37–55.
10. Deakin CD, Nolan JP, Soar J, et al. European Resuscitation 
Council Guidelines for Resuscitation 2010 Section 4. Adult ad-
vanced life support. Resuscitation 2010; 81:1305–1352.
11. Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced 
cardiovascular life support: 2010 American Heart Association 
Guidelines for Cardiopulmonary Resuscitation and Emergency 
Cardiovascular Care. Circulation 2010; 122:S729–S767.
12. Morley PT. Drugs during cardiopulmonary resuscitation. Curr 
Opin Crit Care 2011;17:214–218.
13. Redding JS, Pearson JW. Resuscitation from ventricular fibril-
lation. Drug therapy. JAMA 1968; 203:255–260.
14. Redding JS, Pearson JW. Resuscitation from asphyxia. JAMA 
1962; 182:283–286.
15. Menegazzi JJ, Callaway CW, Sherman LD, et al. Ventricular 
fibrillation scaling exponent can guide timing of defibrillation 
and other therapies. Circulation 2004; 109:926–931.
16. Tang W, Weil MH, Sun S, et al. Epinephrine increases the se-
verity of postresuscitation myocardial dysfunction. Circulation 
1995; 92:3089–3093.
17. Olasveengen TM, Wik L, Sunde K, Steen PA. Outcome when 
adrenaline (epinephrine) was actually given vs. not given-post 
hoc analysis of a randomized clinical trial. Resuscitation 2012; 
83:327-332.
18. Paradis NA, Martin GB, Rosenberg J, et al. The effect of stand-
ard- and high-dose epinephrine on coronary perfusion pressure 
during prolonged cardiopulmonary resuscitation. JAMA 1991; 
265:1139–1144.
19. Larsson PT, Hjemdahl P, Olsson G, et al. Altered platelet func-
tion during mental stress and adrenaline infusion in humans: 
evidence for an increased aggregability in vivo as measured by 
filtragometry. Clin Sci (Lond) 1989; 76:369–376.
20. Dumas F, Cariou A, Manzo-Silberman S, et al. Immediate 
percutaneous coronary intervention is associated with better 
survival after out-of-hospital cardiac arrest: insights from the 
PROCAT (Parisian Region Out of hospital Cardiac ArresT) 
registry. Circ Cardiovasc Interv 2010; 3:200–207.
21. Fries M, Weil MH, Chang YT, et al. Microcirculation during 
cardiac arrest and resuscitation. Crit Care Med 2006; 34(12 
Suppl):S454–S457.
22. Ristagno G, Sun S, Tang W, Castillo C, Weil MH. Effects of 
epinephrine and vasopressin on cerebral microcirculatory flows 
during and after cardiopulmonary resuscitation. Crit Care Med 
2007; 35:2145–2149.
23. Ristagno G, Tang W, Huang L, et al. Epinephrine reduces cer-
ebral perfusion during cardiopulmonary resuscitation. Crit Care 
Med 2009; 37:1408–1415.
24. Hagihara A, Hasegawa M, Abe T, et al. Prehospital epineph-
rine use and survival among patients with out-of-hospital car-
diac arrest. JAMA 2012; 307:1161–1168.
25.  Cao L, Weil MH, Sun S, Tang W. Vasopressor agents for car-
diopulmonary resuscitation. J Cardiovasc Pharmacol Ther 2003; 
8:115–1121.
26. Callaham M, Madsen CD, Barton CW, et al. A randomized 
clinical trial of high-dose epinephrine and norepinephrine vs 
standard-dose epinephrine in prehospital cardiac arrest. JAMA 
1992; 268:2667–2672.
27. Stiell IG, Hébert PC, Wells GA, et al. Vasopressin versus epi-
nephrine for inhospital cardiac arrest: a randomised controlled 
trial. Lancet 2001; 358:105–109.
28. Wenzel V, Krismer AC, Arntz HR, et al. European Resuscita-
tion Council Vasopressor during Cardiopulmonary Resuscita-
tion Study Group. A comparison of vasopressin and epineph-
rine for out-of-hospital cardiopulmonary resuscitation. N Engl J 
Med 2004; 350:105–113.
29. Behringer W, Kittler H, Sterz F, et al. Cumulative epinephrine 
dose during cardiopulmonary resuscitation and neurologic out-
come. Ann Intern Med 1998; 129:450–456.
30. Holmberg M, Holmberg S, Herlitz J. Low chance of survival 
among patients requiring adrenaline (epinephrine) or intuba-
tion after out-of-hospital cardiac arrest in Sweden. Resuscitation 
2002; 54:37–45.
31. Herlitz J, Ekström L, Wennerblom B, et al. Adrenaline in out-
of-hospital ventricular fibrillation. Does it make any difference? 
Resuscitation 1995; 29:195–201.
32. Rittenberger JC, Menegazzi JJ, Callaway CW. Association of 
delay to first intervention with return of spontaneous circula-
tion in a swine model of cardiac arrest. Resuscitation 2007; 
73:154–160.
33. Hayashi Y, Iwami T, Kitamura T, et al. Impact of early intrave-
nous epinephrine administration on outcomes following out-of-
hospital cardiac arrest. Circ J 2012; 76:1639–1645.
34. Olasveengen TM, Sunde K, Brunborg C, et al. Intravenous drug 
administration during out-of-hospital cardiac arrest: a rand-
DRuGS DuRING CPR
245
omized trial. JAMA 2009; 302:2222–2229.
35. Jacobs IG, Finn JC, Jelinek GA, et al. Effect of adrenaline on 
survival in out-of-hospital cardiac arrest: a randomised double-
blind placebo-controlled trial. Resuscitation 2011; 82:1138–1143.
36. Nakahara S, Tomio J, Nishida M, et al. Association between 
timing of epinephrine administration and intact neurologic sur-
vival following out-of-hospital cardiac arrest in Japan: a popu-
lation-based prospective observational study. Acad Emerg Med 
2012; 19:782–792.
37. Nakahara S, Tomio J, Takahashi H, et al. Evaluation of pre-
hospital administration of adrenaline (epinephrine) by emer-
gency medical services for patients with out of hospital cardiac 
arrest in Japan: controlled propensity matched retrospective 
cohort study. BMJ 2013; 347:f6829.
38. The Brain resuscitation clinical trial II study group. A rand-
omized clinical trial of calcium entry blocker administration 
to comatose survivors of cardiac arrest: design, methods, and 
patient characteristics. Controlled Clin Trials 1991; 12:525-545.
39. Warren SA, Huszti E, Bradley SM, et al for the American Heart 
Association’s Get With the Guidelines-Resuscitation (National 
Registry of CPR) Investigators. Adrenaline (epinephrine) dos-
ing period and survival after in-hospital cardiac arrest: A ret-
rospective review of prospectively collected data. Resuscitation 
2014; 85:350-358.
40. Yang G, Xu J, Li T, et al. Role of V1a receptor in AVP-in-
duced restoration of vascular hyporeactivity and its relationship 
to MLCP-MLC20 phosphorylation pathway. J Surg Res 2010; 
161:312–320.
41. Lindner KH, Strohmenger Hu, Ensinger H, et al. Stress hor-
mone response during and after cardiopulmonary resuscitation. 
Anesthesiology 1992; 77:662–668.
42. Lindner KH, Prengel AW, Pfenninger EG, et al. Vasopressin 
improves vital organ blood flow during closed-chest cardiopul-
monary resuscitation in pigs. Circulation 1995; 91:215–221.
43. Wenzel V, Lindner KH, Krismer AC, et al. Repeated adminis-
tration of vasopressin but not epinephrine maintains coronary 
perfusion pressure after early and late administration during 
prolonged cardiopulmonary resuscitation in pigs. Circulation 
1999; 99:1379–1384.
44. Prengel WA, Linstedt u, Zenz M, Wenzel V. Effects of com-
bined administration of vasopressin, epinephrine, and nor-
epinephrine during cardiopulmonary resuscitation in pigs. Crit 
Care Med 2005; 33:2587–2591.
45. Wenzel V, Lindner KH, Krismer AC, et al. Survival with full 
neurologic recovery and no cerebral pathology after prolonged 
cardiopulmonary resuscitation with vasopressin in pigs. J Am 
Coll Cardiol 2000; 35:527–533.
46. Mayr VD, Wenzel V, Voelckel WG, et al. Developing a vaso-
pressor combination in a pig model of adult asphyxial cardiac 
arrest. Circulation 2001;104:1651–1656.
47. Stadlbauer KH, Wagner-Berger HG, Wenzel V, et al. Survival 
with full neurologic recovery after prolonged cardiopulmonary 
resuscitation with a combination of vasopressin and epineph-
rine in pigs. Anesth Analg 2003; 96:1743–1749.
48. Mentzelopoulos S, Zakynthinos S, Siempos I, et al. Vasopressin 
for cardiac arrest: Meta-analysis of randomized controlled tri-
als. Resuscitation 2012; 83:32-39.
49. Lindner KH, Dirks B, Strohmenger Hu, et al. Randomised 
comparison of epinephrine and vasopressin in patients with out-
of-hospital ventricular fibrillation. Lancet 1997; 349:535–537.
50. Callaway CW, Hostler D, Doshi AA, et al. usefulness of vaso-
pressin administered with epinephrine during out-of-hospital 
cardiac arrest. Am J Cardiol 2006; 98:1316–21.
51. Gueugniaud PY, David JS, Chanzy E, et al. Vasopressin and 
epinephrine vs. epinephrine alone in cardiopulmonary resusci-
tation. N Engl J Med 2008; 359:21–30.
52. Mentzelopoulos SD, Zakynthinos SG, Tzoufi M, et al. Vaso-
pressin, epinephrine, and corticosteroids for in-hospital cardiac 
arrest. Arch Intern Med 2009; 169:15-24.
53. Ong ME, Tiah L, Leong BS, et al. A randomised, double-blind, 
multi-centre trial comparing vasopressin and adrenaline in pa-
tients with cardiac arrest presenting to or in the Emergency De-
partment. Resuscitation 2012; 83:953-960.
54. Adrie C, Adib-Conquy M, Laurent I, et al. Successful cardio-
pulmonary resuscitation after cardiac arrest as a “sepsis-like” 
syndrome. Circulation 2002; 106:562-568.
55. Mentzelopoulos SD, Malachias S, Chamos C, et al. Vasopres-
sin, steroids, and epinephrine and neurologically favorable sur-
vival after in-hospital cardiac arrest: a randomized clinical trial. 
JAMA 2013; 310:270-279.
56. Ebell MH, Jang W, Shen Y, Geocadin RG; Get With the 
Guidelines–Resuscitation Investigators. Development and 
Validation of the Good Outcome Following Attempted Resus-
citation (GO-FAR) Score to Predict Neurologically Intact Sur-
vival After In-Hospital Cardiopulmonary Resuscitation. JAMA 
Intern Med 2013; 173:1872-1878.
57. Meaney PA, Nadkarni VM, Kern KB, et al. Rhythms and out-
comes of adult in-hospital cardiac arrest. Crit Care Med 2010; 
38:101-108.
58. Girotra S, Nallamothu BK, Spertus JA, et al. Trends in survival 
after in-hospital cardiac arrest. N Engl J Med 2012; 367:1912-
1920.
59. Ballew KA. Combined vasopressin, steroids, and epinephrine 
improved survival in in-hospital cardiac arrest. Ann Intern Med 
2013;159:JC4.
60. Varvarousi G, Goulas S, Agrogiannis G, et al. Epinephrine, 
vasopressin, and nitroglycerin improve neurologic outcome 
in porcine asphyxial cardiac arrest. Am J Emerg Med 2012; 
30:1549-1554.
61. Xanthos T, Bassiakou E, Koudouna E, et al. Combination phar-
macotherapy in the treatment of experimental cardiac arrest. 
Am J Emerg Med 2009; 27:651-659.
62. Kitsou V, Xanthos T, Stroumpoulis K, et al. Nitroglycerin and 
epinephrine improve coronary perfusion pressure in a porcine 
model of ventricular fibrillation arrest: a pilot study. J Emerg 
Med 2009; 37:369-375.
63. Koudouna E, Xanthos T, Bassiakou E, et al. Levosimendan im-
proves the initial outcome of cardiopulmonary resuscitation in 
a swine model of cardiac arrest. Acta Anaesthesiol Scand 2007; 
51:1123-1129.
246
HOSPITAL CHRONICLES 9(4), 2014
64. Tomaselli GF, Fauci AS, Braunwald E, et al. Principles of elec-
trophysiology. In Harrison’s principles of Internal medicine, 17th 
edition, Columbus, OH, uSA: Mc Graw-Hill, 2008:1410-1416.
65. Kudenchuck PJ, Cobb LA, Copass MK, et al. Amiodarone for 
resuscitation after out-of-hospital cardiac arrest due to ventric-
ular fibrillation. N Engl J Med 1999; 341:871-878.
66. Dorian P, Cass D, Schwartz B, et al. Amiodarone as compared 
with lidocaine for shock-resistant ventricular fibrillation. N Engl 
J Med 2002; 346:884–890.
67. Zuercher M, Kern KB, Indik JH, et al. Epinephrine improves 
24-hour survival in a swine model of prolonged ventricular fi-
brillation demonstrating that early intraosseus is superior to de-
layed intravenous administration. Anesth Analg 2011; 112:884–
890.
68. Pantazopoulos IN, Troupis GT, Pantazopoulos CN, et al. 
Nifekalant in the treatment of life-threatening ventricular tach-
yarrhythmias. World J Cardiol 2011; 3:169–176.
69. Stella VJ, He Q. Cyclodextrins. Toxicol Pathol 2008; 36:30–42.
70. Souney PF, Cooper WD, Cushing DJ. PM101: intravenous ami-
odarone formulation changes can improve medication safety. 
Expert Opin Drug Saf 2010; 9:319-333.
71. Cushing DJ, Adams MP, Cooper WD, et al. Bioequivalence of 
2 intravenous amiodarone formulations in healthy participants. 
J Clin Pharmacol 2009; 49:407–415.
72. http://www.captisol.com/partnerships-collaborations/case-stud-
ies/captisol-and-nexterone/; Accesed March 31, 2014.
73. Ong ME, Pellis T, Link MS. The use of antiarrhythmic drugs 
for adult cardiac arrest: A systematic review. Resuscitation 2011; 
82:665-670.
74. Ji XF, Li CS, Wang S, et al. Comparison of the efficacy of 
nifekalant and amiodarone in a porcine model of cardiac arrest. 
Resuscitation 2010; 81:1031–1036.
75. Nagao K. Nifekalant hydrochloride for patients with cardiac 
arrest caused by shockable rhythm. Circ J 2010; 74:2285–2287.
76. Yasuda S, Sawano H, Hazui H, et al. Report from J-PuLSE 
multicenter registry of patients with shock-resistant out-of-hos-
pital cardiac arrest treated with nifekalant hydrochloride. Circ J 
2010; 74:2308–2313.
77. Nademanee K, Taylor R, Bailey WE, Rieders DE, Kosar EM. 
Treating electrical storm: sympathetic blockade versus ad-
vanced cardiac life support-guided therapy. Circulation 2000; 
102:742–747.
78. Miwa Y, Ikeda T, Mera H, et al. Effects of landiolol, an ultra-
short-acting beta1-selective blocker, on electrical storm refrac-
tory to class III antiarrhythmic drugs. Circ J 2010; 74:856–863.
79. de Oliveira FC, Feitosa-Filho GS, Ritt LE. use of beta-blockers 
for the treatment of cardiac arrest due to ventricular fibrilla-
tion/pulseless ventricular tachycardia: a systematic review. Re-
suscitation 2012; 83:674-683.
80. Manz M, Pfeiffer D, Jung W, Luderitz B. Intravenous treatment 
with magnesium in recurrent persistent ventricular tachycardia. 
New Trends in Arrhythmias 1991; 7:437–442.
81. Tzivoni D, Banai S, Schuger C, et al. Treatment of torsade de 
pointes with magnesium sulfate. Circulation 1988; 77:392–397.
82. Chen F, Lin, Q, Chen, G, et al. Does intravenous magnesium 
benefit patients of cardiac arrest?: A metaanalysis. Hong Kong J 
Emerg Med 2012; 19:103-109.
83. van Alem AP, Post J, Koster RW. VF recurrence: characteris-
tics and patient outcome in out-of-hospital cardiac arrest. Re-
suscitation 2003; 59:181–188.
84. Gazmuri RJ, Weil MH, Bisera J, et al. Myocardial dysfunction 
after successful resuscitation from cardiac arrest. Crit Care Med 
1996; 24:992–1000.
85. Kern KB, Hilwig RW, Rhee KH, et al. Myocardial dysfunction 
after resuscitation from cardiac arrest: An example of global 
myocardial stunning. J Am Coll Cardiol 1996; 28:232–240.
86. Laurent I, Monchi M, Chiche JD, et al. Reversible myocardial 
dysfunction in survivors of out-of-hospital cardiac arrest. J Am 
Coll Cardiol 2002; 40:2110–2116.
87. Xu T, Tang W, Ristagno G, et al. Postresuscitation myocardial 
diastolic dysfunction following prolonged ventricular fibrilla-
tion and cardiopulmonary resuscitation. Crit Care Med 2008; 
36:188–192.
88. Franz MR. Current status of monophasic action potential re-
cording: theories, measurements and interpretations. Cardio-
vasc Res 1999; 41:25–40.
89. Opie LH, Clusin WT. Cellular mechanism for ischemic ventric-
ular arrhythmias. Annu Rev Med 1990; 41:231–238.
90. Shivkumar K, Deutsch NA, Lamp ST, et al. Mechanism of hy-
poxic K loss in rabbit ventricle. J Clin Invest 1997; 100:1782–
1788.
91. An J, Varadarajan SG, Camara A, et al. Blocking Na(+)/H(+) 
exchange reduces [Na(+)](i) and [Ca(2+)](i) load after is-
chemia and improves function in intact hearts. Am J Physiol 
2001; 281:2398–2409.
92. Kusuoka H, Chacko VP, Marban E. Myocardial energetics dur-
ing ventricular fibrillation investigated by magnetization trans-
fer nuclear magnetic resonance spectroscopy. Circ Res 1992; 
71:1111–1122.
93. Imahashi K, Kusuoka H, Hashimoto K, et al. Intracellular so-
dium accumulation during ischemia as the substrate for reper-
fusion injury. Circ Res 1999; 84:1401–1406.
94. Gazmuri RJ, Ayoub IM, Kolarova JD, et al. Myocardial protec-
tion during ventricular fibrillation by inhibition of the sodium-
hydrogen exchanger isoform-1. Crit Care Med 2002; 30:166–171.
95. Karmazyn M, Sawyer M, Fliegel L. The Na(+)/H(+) exchang-
er: a target for cardiac therapeutic intervention. Curr Drug Tar-
gets Cardiovasc Haematol Disord 2005; 5:323–335.
96. Levitsky J, Gurell D, Frishman WH. Sodium ion/hydrogen ion 
exchange inhibition: a new pharmacologic approach to myo-
cardial ischemia and reperfusion injury. J Clin Pharmacol 1998; 
38:887-897.
97. Hendrikx M, Mubagwa K, Verdonck F, et al. New Na+-H+ 
exchange inhibitor HOE 694 improves postischemic function 
and high-energy phosphate resynthesis and reduces Ca2+ 
overload in isolated perfused rabbit heart. Circulation 1994; 
89:2787–2798.
98. Iwai T, Tanonaka K, Inoue R, et al. Mitochondrial damage dur-
ing ischemia determines post-ischemic contractile dysfunction 
in perfused rat heart. J Mol Cell Cardiol 2002; 34:725–738.
DRuGS DuRING CPR
247
99. Karmazyn M, Gan XT, Humphreys RA, et al. The myocardial 
Na+-H+ exchange: structure, regulation, and its role in heart 
disease. Circ Res 1999; 85:777–786.
100. Karmazyn M, Sostaric JV, Gan XT. The myocardial Na+-H+ 
exchanger: a potential therapeutic target for the prevention of 
myocardial ischaemic and reperfusion injury and attenuation 
of postinfarction heart failure. Drugs 2001; 61:375–389.
101. Wang S, Radhakrishnan J, Ayoub IM, et al. Limiting sarcolem-
mal Na+ entry during resuscitation from VF prevents excess 
mitochondrial Ca2+ accumulation and attenuates myocardial 
injury. J Appl Physiol 2007; 103:55–65.
102. Gazmuri RJ, Hoffner E, Kalcheim J, et al. Myocardial protec-
tion during ventricular fibrillation by reduction of proton-driv-
en sarcolemmal sodium influx. J Lab Clin Med 2001; 137:43–55.
103. Ayoub IM, Radhakrishnan J, Gazmuri RJ, et al. Targeting mi-
tochondria for resuscitation from cardiac arrest. Crit Care Med 
2008; 36:440–446.
104. Gazmuri RJ, Ayoub IM, Hoffner E, et al. Successful ventricu-
lar defibrillation by the selective sodium-hydrogen exchanger 
isoform-1 inhibitor cariporide. Circulation 2001; 104:234–239.
105. Ayoub IM, Kolarova JD, Yi Z, et al. Sodium-hydrogen ex-
change inhibition during ventricular fibrillation: Beneficial 
effects on ischemic contracture, action potential duration, rep-
erfusion arrhythmias, myocardial function, and resuscitability. 
Circulation 2003; 107:1804–1809.
106. Ayoub IM, Kolarova J, Kantola RL, et al. Cariporide mini-
mizes adverse myocardial effects of epinephrine during re-
suscitation from ventricular fibrillation. Crit Care Med 2005; 
33:2599–2605.
107. Kolarova J, Yi Z, Ayoub IM, et al. Cariporide potentiates the 
effects of epinephrine and vasopressin by nonvascular mecha-
nisms during closed-chest resuscitation. Chest 2005; 127:1327– 
1334.
108. Kolarova JD, Ayoub IM, Gazmuri RJ. Cariporide enables 
hemodynamically more effective chest compression by left-
ward shift of its flow-depth relationship. Am J Physiol Heart 
Circ Physiol 2005; 288:2904–2911.
109. Gazmuri RJ, Ayoub IM. The case for sodium-hydrogen ex-
changer isoform-1 inhibition during cardiac resuscitation re-
mains strong. Crit Care Med 2006; 34:1580–1582.
110. Ayoub IM, Kolarova J, Kantola R, et al. Zoniporide preserves 
left ventricular compliance during ventricular fibrillation and 
minimizes post-resuscitation myocardial dysfunction through 
benefits on energy metabolism. Crit Care Med 2007; 35:2329–
2336.
111. Ayoub IM, Kolarova J, Gazmuri RJ. Cariporide given dur-
ing resuscitation promotes return of electrically stable and 
mechanically competent cardiac activity. Resuscitation 2009; 
81:106–110.
112. Radhakrishnan J, Ayoub IM, Gazmuri RJ. Activation of cas-
pase-3 may not contribute to postresuscitation myocardial dys-
function. Am J Physiol Heart Circ Physiol 2009; 296:1164–1174.
113. Laver S, Farrow C, Turner D, Nolan J. Mode of death after 
admission to an intensive care unit following cardiac arrest. 
Intensive Care Med 2004; 30:2126–2128.
114. Neumar RW. Molecular mechanisms of ischemic neuronal in-
jury. Ann Emerg Med 2000; 36:483–506.
115. Fujioka M, Taoka T, Matsuo Y, et al. Magnetic resonance im-
aging shows delayed ischemic striatal neurodegeneration. Ann 
Neurol 2003; 54:732–747.
116. Dezfulian C, Raat N, Shiva S, Gladwin MT. Role of the anion 
nitrite in ischemia-reperfusion cytoprotection and therapeu-
tics. Cardiovasc Res 2007; 75:327–338.
117. Duranski MR, Greer JJ, Dejam A, et al. Cytoprotective effects 
of nitrite during in vivo ischemia-reperfusion of the heart and 
liver. J Clin Invest 2005; 115:1232–1240.
118. Jung KH, Chu K, Ko SY, et al. Early intravenous infusion of 
sodium nitrite protects brain against in vivo ischemia-reperfu-
sion injury. Stroke 2006; 37:2744–2750.
119. Gonzalez FM, Shiva S, Vincent PS, et al. Nitrite anion provides 
potent cytoprotective and antiapoptotic effects as adjunctive 
therapy to reperfusion for acute myocardial infarction. Circu-
lation 2008; 117:2986–2994.
120. Pluta RM, Dejam A, Grimes G, et al. Nitrite infusions to pre-
vent delayed cerebral vasospasm in a primate model of sub-
arachnoid hemorrhage. JAMA 2005; 293:1477–1484.
121. Shiva S, Wang X, Ringwood LA, et al. Ceruloplasmin is a NO 
oxidase and nitrite synthase that determines endocrine NO ho-
meostasis. Nat Chem Biol 2006; 2:486–493.
122. Bryan NS, Calvert JW, Elrod JW, et al. Dietary nitrite supple-
mentation protects against myocardial ischemia-reperfusion 
injury. Proc Natl Acad Sci USA 2007; 104:19144–19149.
123. Dejam A, Hunter CJ, Tremonti C, et al. Nitrite Infusion in 
Humans and Nonhuman Primates. Endocrine Effects, Phar-
macokinetics, and Tolerance Formation. Circulation 2007; 
116:1821–1831.
124. Bloch KD, Ichinose F, Roberts JD, Jr, Zapol WM. Inhaled NO 
as a therapeutic agent. Cardiovasc Res 2007; 75:339–348.
125. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous 
modulator of leukocyte adhesion. Proc Natl Acad Sci USA 
1991; 88:4651–4655.
126. Huang Z, Huang PL, Ma J, et al. Enlarged infarcts in endothe-
lial nitric oxide synthase knockout mice are attenuated by 
nitro-l-arginine. J Cereb Blood Flow Metab 1996; 16:981–987.
127. Jones SP, Girod WG, Palazzo AJ, et al. Myocardial ischemia-
reperfusion injury is exacerbated in absence of endothelial cell 
nitric oxide synthase. Am J Physiol 1999; 276:1567–1573.
128. Nishida T, Yu JD, Minamishima S, et al. Protective effects of 
nitric oxide synthase 3 and soluble guanylate cyclase on the 
outcome of cardiac arrest and cardiopulmonary resuscitation 
in mice. Crit Care Med 2009; 37:256–262.
129. Dezfulian C, Shiva S, Alekseyenko A, et al. Nitrite therapy af-
ter cardiac arrest reduces reactive oxygen species generation, 
improves cardiac and neurological function, and enhances 
survival via reversible inhibition of mitochondrial complex I. 
Circulation 2009; 120:897–905.
130. Beiser DG, Orbelyan GA, Inouye BT, et al. Genetic deletion 
of NOS3 increases lethal cardiac dysfunction following mouse 
cardiac arrest. Resuscitation 2011; 82:115–121.
131. Minamishima S, Kida K, Tokuda K, et al. Inhaled nitric oxide 
248
HOSPITAL CHRONICLES 9(4), 2014
improves outcomes after successful cardiopulmonary resusci-
tation in mice. Circulation 2011; 124:1645–1653.
132. Nagasaka Y, Buys E, Spagnolli E, et al. Soluble guanylate 
cyclase alfa 1 is required for the cardioprotective effects of 
inhaled nitric oxide. Am J Physiol Heart Circ Physiol 2011; 
300:1477-1483.
133. Dezfulian C, Alekseyenko A, Dave KR, et al. Nitrite therapy 
is neuroprotective and safe in cardiac arrest survivors. Nitric 
Oxide 2012; 26:241–250.
134. Kida K, Shirozu K, Yu B, et al. Beneficial Effects of nitric ox-
ide on outcomes after cardiac arrest and cardiopulmonary re-
suscitation in hypothermia-treated mice. Anesthesiology 2014; 
120:880-889.
135. Ichinose F, Roberts JD, Jr, Zapol WM. Inhaled nitric oxide: a 
selective pulmonary vasodilator: current uses and therapeutic 
potential. Circulation 2004; 109:3106–3111.
136. Cannon RO, 3rd, Schechter AN, Panza JA, et al. Effects of 
inhaled nitric oxide on regional blood flow are consistent with 
intravascular nitric oxide delivery. J Clin Invest 2001; 108:279–
287.
137. Nagasaka Y, Fernandez BO, Garcia-Saura MF, et al. Brief 
periods of nitric oxide inhalation protect against myocardial 
ischemia-reperfusion injury. Anesthesiology 2008; 109:675–182.
138. Terpolilli NA, Kim SW, Thal SC, et al. Inhalation of nitric 
oxide prevents ischemic brain damage in experimental stroke 
by selective dilatation of collateral arterioles. Circ Res 2012; 
110:727-738.
139. Engdahl J, Bång A, Lindqvist J, et al. Time trends in long-term 
mortality after out-of-hospital cardiac arrest, 1980 to 1998, and 
predictors for death. Am Heart J 2003; 145:826–833.
140. Nichol G, Stiell IG, Laupacis A, et al. A cumulative meta-
analysis of the effectiveness of defibrillator-capable emergency 
medical services for victims of out-of-hospital cardiac arrest. 
Ann Emerg Med 1999; 34:517–525.
141. Hossmann KA. Reperfusion of the brain after global ischemia: 
hemodynamic disturbances. Shock 1997; 8:95–103.
142. Radovsky A, Safar P, Sterz F, et al. Regional prevalence and 
distribution of ischemic neurons in dog brains 96 hours after 
cardiac arrest of 0 to 20 minutes. Stroke 1995; 26:2127–2134.
143. Ouyang YB, Tan Y, Comb M, et al. Survival and death-pro-
moting events after transient cerebral ischemia: phosphoryla-
tion of Akt, release of cytochrome C and activation of caspase-
like proteases. J Cereb Blood Flow Metab 1999; 19:1126–1135.
144. Rockwood K, Brown M, Merry H, et al. Societal costs of vascu-
lar cognitive impairment in older adults. Stroke 2002; 33:1605–
1609.
145. Hopkins RO, Jackson JC. Long-term neurocognitive function 
after critical illness. Chest 2006; 130:869–878.
146. Zola-Morgan S, Squire LR, Rempel NL, et al. Enduring mem-
ory impairment in monkeys after ischemic damage to the hip-
pocampus. J Neurosci 1992; 12:2582–2596.
147. Rempel-Clower NL, Zola SM, Squire LR, et al. Three cases of 
enduring memory impairment after bilateral damage limited 
to the hippocampal formation. J Neurosci 1996; 16:5233–5255.
148. Fries M, Nolte KW, Coburn M, et al. Xenon reduces neu-
rohistopathological damage and improves the early neuro-
logical deficit after cardiac arrest in pigs. Crit Care Med 2008; 
36:2420–2426.
149. Liu W, Khatibi N, Sridharan A, et al. Application of medical 
gases in the field of neurobiology. Med Gas Res 2011; 1:13.
150. Franks NP, Dickinson R, de Sousa SL, et al. How does xenon 
produce anaesthesia? Nature 1998; 396:324.
151. de Sousa SL, Dickinson R, Lieb WR, et al. Contrasting syn-
aptic actions of the inhalational general anesthetics isoflurane 
and xenon. Anesthesiology 2000; 92:1055–1066.
152. Dingledine R, Borges K, Bowie D, et al. The glutamate recep-
tor ion channels. Pharmacol Rev 1999; 51:7–61.
153. Dickinson R, Peterson BK, Banks P, et al. Competitive inhibi-
tion at the glycine site of the N-methyl-D-aspartate receptor by 
the anesthetics xenon and isoflurane: evidence from molecular 
modeling and electrophysiology. Anesthesiology 2007:107:756–
767.
154. Dinse A, Föhr KJ, Georgieff M, et al. Xenon reduces gluta-
mate-, AMPA-, and kainate-induced membrane currents in 
cortical neurones. Br J Anaesth 2005; 94:479–485.
155. Gruss M, Bushell TJ, Bright DP, et al. Two-pore-domain K+ 
channels are a novel target for the anesthetic gases xenon, ni-
trous oxide, and cyclopropane. Mol Pharmacol 2004; 65:443–
452.
156. Bantel C, Maze M, Trapp S. Neuronal preconditioning by in-
halational anesthetics: evidence for the role of plasmalemmal 
adenosine triphosphate-sensitive potassium channels. Anesthe-
siology 2009; 110:986–995.
157. Parsons MW, Li T, Barber PA, et al. Combined (1)H MR 
spectroscopy and diffusionweighted MRI improves the predic-
tion of stroke outcome. Neurology 2000; 55:498–505.
158. Chakkarapani E, Thoresen M, Hobbs CE, et al. A closed-cir-
cuit neonatal xenon delivery system: a technical and practical 
neuroprotection feasibility study in newborn pigs. Anesth An-
alg 2009; 109:451–460.
159. Natale G, Cattano D, Abramo A, et al. Morphological evi-
dence that xenon neuroprotects against N-methyl-DL-aspartic 
acid-induced damage in the rat arcuate nucleus:a time-de-
pendent study. Ann NY Acad Sci 2006; 1074:650–658.
160. Sanders RD, Maze M. Xenon: from stranger to guardian. Curr 
Opin Anaesthesiol 2005; 18:405–411.
161. Hardingham GE, Bading H. The Yin and Yang of NMDA re-
ceptor signaling. Trends Neurosci 2003; 26:81–89.
162. Homi HM, Yokoo N, Ma D, et al. The neuroprotective effect 
of xenon administration during transient middle cerebral ar-
tery occlusion in mice. Anesthesiology 2003; 99:876–881.
163. Coburn M, Kunitz O, Baumert J-H, et al. Randomized con-
trolled trial of the haemodynamic and recovery effects of xe-
non or propofol anaesthesia. Br J Anaesth 2005; 94:198–202.
164. Preckel B, Schlack W, Heibel T, et al. Xenon produces mini-
mal haemodynamic effects in rabbits with chronically compro-
mised left ventricular function. Br J Anaesth 2002; 88:264–269.
165. Dingley J, Tooley J, Porter H, et al. Xenon provides short-term 
neuroprotection in neonatal rats when administered after hy-
poxia/ischemia. Stroke 2006; 37:501–506.
DRuGS DuRING CPR
249
166. Chakkarapani E, Dingley J, Liu X, et al. Xenon enhances hy-
pothermic neuroprotection in asphyxiated newborn pigs. Ann 
Neurol 2010; 68:330–341.
167. Fries M, Brücken A, Çizen A, et al. Combining xenon and mild 
therapeutic hypothermia preserves neurological function after 
prolonged cardiac arrest in pigs. Crit Care Med 2012; 40:1297-
1303.
168. Hobbs C, Thoresen M, Tucker A, et al. Xenon and hypother-
mia combine additively, offering long-term functional and his-
topathologic neuroprotection after neonatal hypoxia/ischemia. 
Stroke 2008; 39:1307–1313.
169. Arola O, Laitio R, Roine R, et al. Feasibility and cardiac safety 
of inhaled xenon in combination with therapeutic hypothermia 
following out-of-hospital cardiac arrest. Critical Care Medicine 
2013; 41:2116-2124.
170. Ye Z, Zhang R, Sun X. Bustling argon: biological effect. Med 
Gas Res 2013; 3:22.
171. Coburn M, Sanders RD, Ma D, et al. Argon: the ‘lazy’ noble 
gas with organoprotective properties. Eur J of Anaesthesiol 
2012; 29:549–551.
172. Brucken A, Cizen A, Fera C, et al. Argon reduces neurohisto-
pathological damage and preserves functional recovery after 
cardiac arrest in rats. Br J Anaesth 2013; 110:106–112.
173. Zhuang L, Yang T, Zhao H, et al. The protective profile of 
argon, helium, and xenon in a model of neonatal asphyxia in 
rats. Crit Care Med 2012; 40:1724–1730.
174. Pagel PS, Krolikowski JG, Shim YH, et al. Noble gases without 
anesthetic properties protect myocardium against infarction 
by activating prosurvival signaling kinases and inhibiting mi-
tochondrial permeability transition in vivo. Anesth Analg 2007; 
105:562–569.
175. Rizvi M, Jawad N, Li Y, et al. Effect of noble gases on oxygen 
and glucose deprived injury in human tubular kidney cells. Exp 
Biol Med (Maywood) 2010; 235:886–891.
176. Irani Y, Pype JL, Martin AR, et al. Noble gas (argon and 
xenon)-saturated cold storage solutions reduce ischemia-rep-
erfusion injury in a rat model of renal transplantation. Nephron 
Extra 2011; 1:272–282.
177. Ristagno G, Fumagalli F, Russo I. Postresuscitation treatment 
with argon improves early neurological recovery in a porcine 
model of cardiac arrest. Shock 2014; 41;72-78.
178. Koliantzaki I, Zakynthinos S, Mentzelopoulos SD. The poten-
tial contribution of corticosteroids to positive cardiac arrest 
outcomes. In: Gullo A, Ristagno G, eds. Resuscitation, Trans-
lational Research, Clinical Evidence, Education, Guidelines. 
Springer-Verlag, Milan, Italy, 2014: 143-155.
179. Libby P, Maroko PR, Bloor CM, et al. Reduction of experi-
mental myocardial infarct size by corticosteroid administra-
tion. J Clin Invest 1973; 52:599–607.
180. Spath JA Jr, Lane DL, Lefer AM. Protective action of methyl-
prednisolone on the myocardium during experimental myocar-
dial ischemia in the cat. Circ Res 1974; 35:44–51.
181. Hammerman H, Kloner RA, Hale S, et al. Dose-dependent ef-
fects of short-term methylprednisolone on myocardial infarct 
extent, scar formation, and ventricular function. Circulation 
1983; 68:446–452.
182. Wynsen JC, Preuss KC, Gross GJ, et al. Steroid-induced en-
hancement of functional recovery of postischemic, reperfused 
myocardium in conscious dogs. Am Heart J 1988; 116:915–925.
183. D’Amico M, Di Filippo C, La M, et al. Lipocortin 1 reduces 
myocardial ischemia-reperfusion injury by affecting local leu-
kocyte recruitment. FASEB J 2000; 14:1867–1869.
184. Valen G, Kawakami T, Tähepold P, et al. Glucocorticoid pre-
treatment protects cardiac function and induces cardiac heat 
shock protein 72. Am J Physiol 2000; 279:836–843.
185. Sun L, Chang J, Kirchhoff SR, et al. Activation of HSF and 
selective increase in heat-shock proteins by acute dexametha-
sone treatment. Am J Physiol 2000; 278:1091–1097.
186. Giugliano GR, Giugliano RP, Gibson CM, Kuntz RE. Meta-
analysis of corticosteroid treatment in acute myocardial infarc-
tion. Am J Cardiol 2003; 91:1055-1059.
187. Cronstein BN, Kimmel SC, Levin RI, et al. A mechanism for 
the anti-inflammatory effects of corticosteroids: the glucocor-
ticoid receptor regulates leukocyte adhesion to endothelial 
cells and expression of endothelial-leukocyte adhesion mol-
ecule 1 and intercellular adhesion molecule 1. Proc Natl Acad 
Sci USA 1992; 89:9991–9995.
188. Springer TA. Traffic signals for lymphocyte recirculation and 
leukocyte emigration: the multistep paradigm. Cell 1994; 76: 
301–314.
189. Filep JG, Delalandre A, Payette Y, et al. Glucocorticoid re-
ceptor regulates expression of L-selectin and CD11/CD18 on 
human neutrophils. Circulation 1997; 96:295–301.
190. Nakagawa M, Bondy GP, Waisman D, et al. The effect of glu-
cocorticoids on the expression of L-selectin on polymorphonu-
clear leukocyte. Blood 1999; 93: 2730–2737.
191. Radomski MW, Palmer RMJ, Moncada S. Glucocorticoids in-
hibit the expression of an inducible, but not the constitutive, 
nitric oxide synthase in vascular endothelial cells. Proc Natl 
Acad Sci USA 1990; 87:10043–10047.
192. Amano Y, Lee SW, Allison AC. Inhibition by glucocorticoids 
of the formation of interleukin-1 alpha, interleukin-1 beta, and 
interleukin-6: mediation by decreased mRNA stability. Mol 
Pharmacol 1993; 43:176–182.
193. Teoh KHT, Bradley CA, Gauldie J, et al. Steroid inhibition of 
cytokine-mediated vasodilation after warm heart surgery. Cir-
culation 1995; 92(Suppl II):347-363.
194. Williams CM, Coleman JW. Induced expression of mRNA for 
IL-5, IL-6, TNF-alpha, MIP-2 and IFN-gamma in immuno-
logically activated rat peritoneal mast cells: inhibition by dexa-
methasone and cyclosporin A. Immunology 1995; 86:244–249.
195. Meng X, Ao L, Brown JM, et al. LPS induces late cardiac func-
tional protection against ischemia independent of cardiac and 
circulating TNF-alpha. Am J Physiol 1997; 42:1894–1904.
196. Minneci PC, Deans KJ, Banks SM, et al. Corticosteroids for 
septic shock. Ann Intern Med 2004; 141:742–743.
197. Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy 
for patients with septic shock. N Engl J Med 2008; 358:111–124.
198. Annane D, Sebille V, Charpentier C, et al. Effect of treatment 
with low doses of hydrocortisone and fludrocortisone on mor-
250
HOSPITAL CHRONICLES 9(4), 2014
tality in patients with septic shock. JAMA 2002; 288:862–871.
199. Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis 
Campaign: International Guidelines for Management of Se-
vere Sepsis and Septic Shock, 2012. Intensive Care Med 2013; 
39:165–228.
200. Adrie C, Laurent I, Monchi M, et al. Postresuscitation disease 
after cardiac arrest: a sepsis-like syndrome? Curr Opin Crit 
Care 2004; 10:208-212.
201. Neumar RW, Nolan JP, Adrie C, et al. Post-cardiac arrest syn-
drome: epidemiology, pathophysiology, treatment, and prog-
nostication. A consensus statement from the ILCR, AHA, 
ANZCR, ERC, HSFC, IAHF, RCA, RCSA; AHA ECCC; 
CCSA; CCPCC; CCC; SC. Circulation 2008; 118:2452-2483.
202. Peberdy MA, Callaway CW, Neumar RW, et al. American 
Heart Association. Part 9: post-cardiac arrest care: 2010 AHA 
Guidelines for Cardiopulmonary Resuscitation and Emergency 
Cardiovascular Care. Circulation 2010; 122(Suppl 3):768-786.
203. Kosaka Y, Quillinan N, Bond C, et al. GPER1/GPR30 acti-
vation improves neuronal survival following global cerebral 
ischemia induced by cardiac arrest in mice. Transl Stroke Res 
2012; 3:500-507.
204. Noppens RR, Kofler J, Grafe MR, et al. Estradiol after cardiac 
arrest and cardiopulmonary resuscitation is neuroprotective 
and mediated through estrogen receptor-beta. J Cereb Blood 
Flow Metab 2009; 29:277–286.
205. Hutchens MP, Nakano T, Kosaka Y, et al. Estrogen is reno-
protective via a nonreceptor-dependent mechanism after car-
diac arrest in vivo. Anesthesiology 2010; 112:395-405.
206. De Luca L, Colucci WS, Nieminen MS, et al. Evidence-based 
use of levosimendan in different clinical settings. Eur Heart J 
2006; 27:1908-1920.
207. Kelm RF, Wagenführer J, Bauer H, et al. Effects of levosi-
mendan on hemodynamics, local cerebral blood flow, neuronal 
injury, and neuroinflammation after asphyctic cardiac arrest 
in rats. Crit Care Med 2014. [Epub ahead of print; PMID: 
24633188].
208. Rungatscher A, Linardi D, Tessari M, et al. Levosimendan is 
superior to epinephrine in improving myocardial function af-
ter cardiopulmonary bypass with deep hypothermic circulatory 
arrest in rats. J Thorac Cardiovasc Surg 2012; 143;209-214.
209. Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses 
the blood-brain barrier to protect against experimental brain 
injury. Proc Natl Acad Sci USA 2000; 97:10526–10531.
210. Siren AL, Fratelli M, Brines M, et al. Erythro-poietin prevents 
neuronal apoptosis after cerebral ischemia and metabolic 
stress. Proc Natl Acad Sci USA 2001; 98:4044–4049.
211. Ruscher K, Freyer D, Karsch M, et al. Erythropoietin is a par-
acrine mediator of ischemic tolerance in the brain: evidence 
from an in vitro model. J Neurosci 2002; 22:10291–10301.
212. Ghezzi P, Brines M. Erythropoietin as an antiapoptotic, tissue-
protective cytokine. Cell Death Differ 2004; 11:37–44.
213. Cai Z, Manalo DJ, Wei G, et al. Hearts from rodents exposed 
to intermittent hypoxia or erythropoietin are protected against 
ischemia-reperfusion injury. Circulation 2003; 108:79–85.
214. Calvillo L, Latini R, Kajstura J, et al. Recombinant human 
erythropoietin protects the myocardium from ischemia-reper-
fusion injury and promotes beneficial remodeling. Proc Natl 
Acad Sci USA 2003; 100:4802–4806.
215. Moon C, Krawczyk M, Ahn D, et al. Erythropoietin reduces 
myocardial infarction and left ventricular functional decline 
after coronary artery ligation in rats. Proc Natl Acad Sci USA 
2003; 100:11612–11617.
216. Parsa CJ, Matsumoto A, Kim J, et al. A novel protective ef-
fect of erythropoietin in the infarcted heart. J Clin Invest 2003; 
112:999–1007.
217. Tramontano AF, Muniyappa R, Black AD, et al. Erythropoi-
etin protects cardiac myocytes from hypoxia-induced apopto-
sis through an Akt-dependent pathway. Biochem Biophys Res 
Commun 2003; 308:990–994.
218. Cai Z, Semenza GL. Phosphatidylinositol-3-kinase signaling is 
required for erythropoietin-mediated acute protection against 
myocardial ischemia/reperfusion injury. Circulation 2004; 109: 
2050–2053.
219. Lipsic E, van der MP, Henning RH, et al. Timing of eryth-
ropoietin treatment for cardioprotection in ischemia/reperfu-
sion. J Cardiovasc Pharmacol 2004; 44:473–479.
220. Parsa CJ, Kim J, Riel Ru, et al. Cardioprotective effects of 
erythropoietin in the reperfused ischemic heart: a potential 
role for cardiac fibroblasts. J Biol Chem 2004; 279:20655-20662.
221. Wright GL, Hanlon P, Amin K, et al. Erythropoietin recep-
tor expression in adult rat cardiomyocytes is associated with an 
acute cardioprotective effect for recombinant erythropoietin 
during ischemia-reperfusion injury. FASEB J 2004; 18:1031-
1033.
222. Namiuchi S, Kagaya Y, Ohta J, et al. High serum erythropoi-
etin level is associated with smaller infarct size in patients with 
acute myocardial infarction who undergo successful primary 
percutaneous coronary intervention. J Am Coll Cardiol 2005; 
45:1406–1412.
223. Vesey DA, Cheung C, Pat B, et al. Erythropoietin protects 
against ischaemic acute renal injury. Nephrol Dial Transplant 
2004; 19:348–355. 
224. Abdelrahman M, Sharples EJ, McDonald MC, et al. Eryth-
ropoietin attenuates the tissue injury associated with hemor-
rhagic shock and myocardial ischemia. Shock 2004; 22:63–69.
225. Incagnoli P, Ramond A, Joyeux-Faure M, et al. Erythropoietin 
improved initial resuscitation and increased survival after car-
diac arrest in rats. Resuscitation 2009; 80:696–700.
226. Huang C, Hsu C, Chen H, et al. Erythropoietin improves the 
postresuscitation myocardial dysfunction and survival in the 
asphyxia-induced cardiac arrest model. Shock 2007; 28:53–58.
227. Grmec S, Strnad M, Kupnik D, et al. Erythropoietin facilitates 
the return of spontaneous circulation and survival in victims of 
out-of-hospital cardiac arrest. Resuscitation 2009; 80:631-637.
228. Cariou A, Claessens Y, Pene F, et al. Early high-dose erythro-
poietin and hypothermia after out-of-hospital cardiac arrest: a 
matched control study. Resuscitation 2008; 76:397-404.
229. Xanthos T, Vasileiou P; Kakavas S, et al. The potential role 
of erythropoietin as a pleiotropic agent in post-cardiac arrest 
syndrome. Current Pharmaceutical Design 2011; 17;1517-1529.
